Less than a month after confirming its closely-watched MYSTIC lung cancer trial of Imfinzi (durvalumab) plus tremelimumab had failed, AstraZeneca PLC has presented the full results from the study which suggest that there may still be a place for the PD-L1 inhibitor as a first-line treatment for the disease.
In November, AstraZeneca confirmed that in MYSTIC, Imfinzi in combination with the firm's investigational anti-CTLA-4 antibody tremelimumab improved neither overall...






